Mineralys Therapeutics

US · MLYS #2760 by market cap Listed 2023

22.09 +0.14 +0.64%

Live - 5344 symbols - heartbeat 2s ago · 2026-10-08 08:18

Pre-market 22.50 +1.86%

After-hours 22.38 +1.31%

Overnight 22.50 +1.86%

Market cap: 1.95B
P/E (TTM): -5.26
P/B: 3.54
EPS: -2.29
Div yield: 0.00%
52W pos: 2%

Reader sentiment Are you bullish or bearish on MLYS?

Anonymous reader poll. Unscientific, not investment advice.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Founded: 2019
CEO: Mr. Jon Congleton
Employees: 76
Headquarters: Radnor, Pennsylvania, United States of America
Fiscal year end: 12-31
Website: mineralystx.com

Company profile

Exchange: US
Symbol: MLYS
Market-cap rank: #2760
Listing date: 2023-02-10
Market cap: 1.95B
Float cap: 1.47B
Shares out: 88.41M
Float shares: 66.60M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 08:18:44 · For reference only, not investment advice and not tailored to your situation.